サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1404004

多嚢胞性卵巣症候群治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、流通チャネル別、地域別

Polycystic Ovary Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 306 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
多嚢胞性卵巣症候群治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、流通チャネル別、地域別
出版日: 2023年12月28日
発行: Fairfield Market Research
ページ情報: 英文 306 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の多嚢胞性卵巣症候群（PCOS）治療の市場規模は、2024年末時点で42億米ドルになるとみられ、2031年には61億1,000万米ドルと大幅な拡大になると予測されています。女性に影響を及ぼす複雑な内分泌疾患であるPCOSは、卵巣嚢腫、不妊症、内分泌変動を特徴とします。

多嚢胞性卵巣症候群（PCOS）は、世界の健康上の大きな課題であり、世界中で数100万人の女性に影響を及ぼしています。世界保健機関（WHO）によると、世界で1億1,600万人以上の女性（3.4％）がPCOSに苦しんでいます。米国だけでも、PCOSは生殖年齢にある女性の6％から12％を占めており、女性不妊症の主要な原因となっています。

PCOSは特定の年齢層に限定されるものではなく、閉経後の女性でも持続する可能性があり、代謝の変化や心血管疾患のリスク上昇につながります。早期の診断と治療は、症状を緩和するだけでなく、長期的な影響を防ぐためにも極めて重要です。

PCOSとそれに関連するリスクに対する認識が高まるにつれ、診断と治療に対する需要が高まっています。PCOS啓発協会（PCOSAA）のような啓発プログラムやイニシアチブは、診断率の向上に寄与しています。

PCOSの診断件数の増加に対応するため、メーカーは医薬品や栄養補助食品の種類を増やしています。革新的な代替品や治療法の改善は、採用率を高めると予想されます。

FDAが承認したPCOS治療薬は限られているため、個人は異なる目的で使用される適応外治療薬を使用せざるを得ない状況です。PCOS関連症状に対するFDA承認の治療薬がないことが市場成長の妨げとなっています。

低開発経済圏では、PCOSとその症状に関する認識が著しく低いままです。これは、治療に対する理解不足やのんきな態度と相まって、市場拡大の妨げとなる可能性があります。

当レポートでは、世界の多嚢胞性卵巣症候群治療市場について調査し、市場の概要とともに、薬剤クラス別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の多嚢胞性卵巣症候群（PCOS）治療市場の見通し、2018年～2031年

  • 世界の多嚢胞性卵巣症候群（PCOS）治療市場の見通し、薬剤クラス別、金額（10億米ドル）、2018年～2031年
  • 世界の多嚢胞性卵巣症候群（PCOS）治療市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
  • 世界の多嚢胞性卵巣症候群（PCOS）治療市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の多嚢胞性卵巣症候群（PCOS）治療市場の見通し、2018年～2031年

第5章 欧州の多嚢胞性卵巣症候群（PCOS）治療市場の見通し、2018年～2031年

第6章 アジア太平洋の多嚢胞性卵巣症候群（PCOS）治療市場の見通し、2018年～2031年

第7章 ラテンアメリカの多嚢胞性卵巣症候群（PCOS）治療市場の見通し、2018年～2031年

第8章 中東・アフリカの多嚢胞性卵巣症候群（PCOS）治療市場の見通し、2018年～2031年

第9章 競合情勢

  • 薬剤クラス別と流通チャネル別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Novartis AG
    • Sanofi
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc. (Merck group)
    • AstraZeneca plc.
    • Bayer AG
    • Abbott
    • Pfizer, Inc
    • Bristol-Myer Squibb Company
    • Ferring Pharmaceuticals, Inc.
    • Johnson and Johnson
    • Mylan N.V.
    • Allergan plc.
    • GlaxoSmithKline
    • Lupin Pharmaceuticals
    • AbbVie
    • Takeda
    • BIOCAD Global
    • Blairex Laboratories Inc

第10章 付録

目次

The global polycystic ovary syndrome (PCOS) treatment market, valued at US$ 4.2 billion at the end of 2024, is forecasted to witness substantial growth, with an estimated valuation of US$ 6.11 billion by 2031. PCOS, a complex endocrine condition affecting women, is characterized by ovarian cysts, subfertility, and endocrine variations.

PCOS: A Global Health Concern

Polycystic ovarian syndrome (PCOS) poses a significant global health challenge, affecting millions of women worldwide. According to the World Health Organization (WHO), over 116 million women (3.4%) globally suffer from PCOS. In the United States alone, PCOS accounts for 6% to 12% of cases among women of reproductive age, making it a leading cause of female infertility.

PCOS is not limited to a specific age group, as it can persist even in postmenopausal women, leading to metabolic changes and an increased risk of cardiovascular disease. Early diagnosis and treatment are crucial not only to alleviate symptoms but also to prevent long-term consequences.

Opportunities for PCOS Drug Manufacturers:

Changing Lifestyles and Rising Awareness: With a growing awareness of PCOS and its associated risks, there is an increasing demand for diagnosis and treatment. Awareness programs and initiatives, such as PCOS Awareness Association (PCOSAA), are contributing to higher diagnosis rates.

Innovative Treatment Modalities: Manufacturers are offering an expanded range of drug formulations and dietary products to cater to the rising number of PCOS diagnoses. Innovative alternatives and improved treatment options are expected to boost adoption rates.

Challenges Faced by Market Players:

Unavailability of FDA-Approved Drugs: Limited FDA-approved drugs for PCOS treatment force individuals to use off-label drugs intended for different purposes. The absence of FDA-approved treatments for PCOS-related symptoms hinders market growth.

Lack of Awareness in Underdeveloped Economies: In underdeveloped economies, awareness regarding PCOS and its symptoms remains significantly low. This, coupled with a lack of understanding and a carefree attitude towards treatment, can hinder market expansion.

Country-Wise Insights:

Lucrative U.S. Market: The United States experiences rising healthcare costs and an increasing prevalence of PCOS-related disorders. Improved healthcare infrastructure, rising disposable income, and government-led awareness initiatives contribute to market growth.

Growing Indian Market: India has witnessed a surge in PCOS diagnoses, with approximately 22.5% of women affected. Increased awareness, changing lifestyles, and dietary habits are driving the demand for PCOS treatment in the country.

Competitive Landscape:

Leading manufacturers and pharmaceutical companies are focusing on developing innovative products to strengthen their global product pipelines. Collaborations and consolidation activities with other firms are being pursued to expedite research, development, and distribution.

Key Companies Profiled:

  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • Merck & Co., Inc. (Merck group)
  • AstraZeneca plc.
  • Bayer AG
  • Abbott
  • Pfizer, Inc
  • Bristol-Myer Squibb Company
  • Ferring Pharmaceuticals, Inc.
  • Johnson and Johnson
  • Mylan N.V.
  • Allergan plc.
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • AbbVie
  • Takeda
  • BIOCAD Global
  • Blairex Laboratories Inc
  • Agile Therapeutics

Key Segments of PCOS Treatment Industry Research

By Drug Class:

  • Oral Contraceptives
  • Insulin Sensitizing Agents
  • Antidepressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores/OTC
  • e-Commerce
  • Clinics

By Region:

  • North America
  • Latin America
  • Europe Polycystic
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Oral Contraceptives
      • 3.1.1.2. Insulin Sensitizing Agents
      • 3.1.1.3. Antidepressants
      • 3.1.1.4. Ornithine Decarboxylase Inhibitors
      • 3.1.1.5. Aromatase Inhibitors & SERMs
      • 3.1.1.6. Diuretics
  • 3.2. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Drug Stores/OTC
      • 3.2.1.3. e-Commerce
      • 3.2.1.4. Clinics
  • 3.3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Oral Contraceptives
      • 4.1.1.2. Insulin Sensitizing Agents
      • 4.1.1.3. Antidepressants
      • 4.1.1.4. Ornithine Decarboxylase Inhibitors
      • 4.1.1.5. Aromatase Inhibitors & SERMs
      • 4.1.1.6. Diuretics
  • 4.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Drug Stores/OTC
      • 4.2.1.3. e-Commerce
      • 4.2.1.4. Clinics
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Oral Contraceptives
      • 5.1.1.2. Insulin Sensitizing Agents
      • 5.1.1.3. Antidepressants
      • 5.1.1.4. Ornithine Decarboxylase Inhibitors
      • 5.1.1.5. Aromatase Inhibitors & SERMs
      • 5.1.1.6. Diuretics
  • 5.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Drug Stores/OTC
      • 5.2.1.3. e-Commerce
      • 5.2.1.4. Clinics
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Oral Contraceptives
      • 6.1.1.2. Insulin Sensitizing Agents
      • 6.1.1.3. Antidepressants
      • 6.1.1.4. Ornithine Decarboxylase Inhibitors
      • 6.1.1.5. Aromatase Inhibitors & SERMs
      • 6.1.1.6. Diuretics
  • 6.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Drug Stores/OTC
      • 6.2.1.3. e-Commerce
      • 6.2.1.4. Clinics
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Oral Contraceptives
      • 7.1.1.2. Insulin Sensitizing Agents
      • 7.1.1.3. Antidepressants
      • 7.1.1.4. Ornithine Decarboxylase Inhibitors
      • 7.1.1.5. Aromatase Inhibitors & SERMs
      • 7.1.1.6. Diuretics
  • 7.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Drug Stores/OTC
      • 7.2.1.3. e-Commerce
      • 7.2.1.4. Clinics
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Oral Contraceptives
      • 8.1.1.2. Insulin Sensitizing Agents
      • 8.1.1.3. Antidepressants
      • 8.1.1.4. Ornithine Decarboxylase Inhibitors
      • 8.1.1.5. Aromatase Inhibitors & SERMs
      • 8.1.1.6. Diuretics
  • 8.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Drug Stores/OTC
      • 8.2.1.3. e-Commerce
      • 8.2.1.4. Clinics
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drug Class vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Sanofi
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Teva Pharmaceutical Industries Limited
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc. (Merck group)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. AstraZeneca plc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Bayer AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Abbott
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Pfizer, Inc
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Bristol-Myer Squibb Company
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Ferring Pharmaceuticals, Inc.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Therapy Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Johnson and Johnson
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Therapy Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Mylan N.V.
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Therapy Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Allergan plc.
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Therapy Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. GlaxoSmithKline
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Therapy Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Lupin Pharmaceuticals
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Therapy Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development
    • 9.4.16. AbbVie
      • 9.4.16.1. Company Overview
      • 9.4.16.2. Therapy Portfolio
      • 9.4.16.3. Financial Overview
      • 9.4.16.4. Business Strategies and Development
    • 9.4.17. Takeda
      • 9.4.17.1. Company Overview
      • 9.4.17.2. Therapy Portfolio
      • 9.4.17.3. Financial Overview
      • 9.4.17.4. Business Strategies and Development
    • 9.4.18. BIOCAD Global
      • 9.4.18.1. Company Overview
      • 9.4.18.2. Therapy Portfolio
      • 9.4.18.3. Financial Overview
      • 9.4.18.4. Business Strategies and Development
    • 9.4.19. Blairex Laboratories Inc
      • 9.4.19.1. Company Overview
      • 9.4.19.2. Therapy Portfolio
      • 9.4.19.3. Financial Overview
      • 9.4.19.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations